Compare Neurocrine Biosciences Inc (NBIX) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.97. The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PDBC | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $185.50 | $18.91 |
52-Week Low | $123.10 | $12.90 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.97, up 0.79% today, with a strong bullish technical signal from moving averages. Recent news highlights institutional accumulation, with Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (SEC filing, July 19, 2026), and commodities gaining attention as an inflation hedge amid Middle East tensions.
The ETF offers diversified commodity exposure without K-1 tax forms, but faces risks from commodity price volatility and geopolitical events. While technical momentum is positive, a Seeking Alpha report from June 11, 2026, downgraded PDBC to hold due to weakening commodity momentum, indicating cautious near-term outlook despite long-term inflation-hedging appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
